A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)-Reference-Cited by-同舟云学术

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)

Published:2016-02-09 Issue:3 Volume:91 Page:308-312
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Zent Clive S.¹,Victoria Wang Xin²,Ketterling Rhett P.³,Hanson Curtis A.³,Libby Edward N.⁴,Barrientos Jacqueline C.⁵,Call Timothy G.³,Chang Julie E.⁶,Liu Jane J.⁷,Calvo Alejandro R.⁸,Lazarus Hillard M.⁹,Rowe Jacob M.¹⁰,Luger Selina M.¹¹,Litzow Mark R.³,Tallman Martin S.¹²

Affiliation:

1. University of Rochester Medical Center, Rochester, New York (Current Location) Mayo Clinic; Rochester Minnesota (Former Location)

2. Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center; Boston Massachusetts

3. Mayo Clinic; Rochester Minnesota

4. Seattle Cancer Care Alliance, Seattle, Washington (Current Location) University of New Mexico Cancer Center; Albuquerque NM

5. North Shore-LIJ Health System NCORP; Manhasset New York

6. University of Wisconsin; Madison Wisconsin

7. Illinois CancerCare; Peoria Illinois

8. Kettering Health Network; Kettering Ohio

9. Case Western Reserve University; Cleveland Ohio

10. Rambam Medical Center; Haifa Israel

11. University of Pennsylvania; Philadelphia Pennsylvania

12. Memorial Sloan Kettering Cancer Center, New York, New York (Current Location) Northwestern University School of Medicine; Chicago Illinois (Former Location)

Funder

Public Health Service Grants from the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24265/fullpdf

Reference34 articles.

1. Howlader N Noone A Krapcho M http://seer.cancer.gov/csr/1975_2012/ 2015

2. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010